Contineum Therapeutics (Contineum Therapeutics) EPS (Basic) : $-0.60 (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics EPS (Basic)?

Contineum Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.31. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.60.

Contineum Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.60.

Contineum Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.31. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -0.59.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Contineum Therapeutics EPS (Basic) Historical Data

The historical data trend for Contineum Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics EPS (Basic) Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

EPS (Basic)

-1.74

-1.46

1.36

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial			-0.45	-0.29	-	-0.29	-0.31

Contineum Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Contineum Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(22.72	-	0)	/	16.674
	=	1.36

Contineum Therapeutics's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.417	-	0)	/	27.056
	=	-0.31

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.60

Contineum Therapeutics (NAS:CTNM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Contineum Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024